Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor
- 1 November 2005
- journal article
- review article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 64 (suppl_4), iv29-iv30
- https://doi.org/10.1136/ard.2005.042390
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic reviewThe Lancet Infectious Diseases, 2004
- Tuberculosis following the Use of Etanercept, a Tumor Necrosis Factor InhibitorClinical Infectious Diseases, 2004
- Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor AntagonistsClinical Infectious Diseases, 2004
- Infections and anti–tumor necrosis factor α therapyArthritis & Rheumatism, 2003
- Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infectionThe Lancet Infectious Diseases, 2003
- TNF-alpha blockade and tuberculosis: better look before you leap.2003
- Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical managementThe Lancet Infectious Diseases, 2003
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Hepatotoxicity Associated With Isoniazid Preventive TherapyPublished by American Medical Association (AMA) ,1999
- Mycobacterium tuberculosisInfection in Solid‐Organ Transplant Recipients: Impact and Implications for ManagementClinical Infectious Diseases, 1998